On April 24, 2023, the World Health Organization (WHO) prequalified Coartem Baby (artemether-lumefantrine), marking a significant advancement in malaria treatment for newborns and infants. This treatment is specifically formulated for infants weighing between 2 kg and 5 kg and is presented as a dissolvable tablet with a sweet cherry flavor, making it easier for caregivers to administer. Novartis is providing this treatment largely on a not-for-profit basis in malaria-endemic regions, addressing a critical gap in safe treatment options for this vulnerable population. Previously, infants under 5 kg had to rely on crushed adult tablets, which posed risks of dosing errors and side effects. The approval was supported by the CALINA study, a clinical trial that determined the appropriate dosage for infants. Additionally, WHO has prequalified three new rapid diagnostic tests designed to detect malaria strains that evade standard testing methods. These tests target the pLDH enzyme, providing a more reliable diagnosis, especially in regions where the malaria parasite has mutated and is no longer detectable by traditional tests. This development is expected to enhance malaria treatment and detection across several African countries, starting with Ghana.